Literature DB >> 35213752

Cytokine induced 3-D organotypic psoriasis skin model demonstrates distinct roles for NF-κB and JAK pathways in disease pathophysiology.

Viktor Todorović1, Heath A McDonald1, Paul Hoover2, Joseph B Wetter1, Anastasia E Marinopoulos1, Clarissa L Woody1, Loan Miller1, Ariel Finkielsztein2, Robert W Dunstan3, Amy S Paller2, Prisca Honore1, Spiro Getsios2, Victoria E Scott1.   

Abstract

Psoriasis vulgaris is an inflammatory skin disease that affects 2%-3% of the population worldwide. One of the major challenges in discovering novel therapies is the poor translatability of animal models to human disease. Therefore, it is imperative to develop human preclinical models of psoriasis that are amenable to pharmacological intervention. Here, we report a 3-D reconstituted human epidermis (RHE) culture system treated with cytokines commonly associated with psoriasis (TNFα, IL-17A and IL-22) that reproduced some key features of the human disease. The effects on epidermal morphology, gene transcription and cytokine production, which are dysregulated in psoriasis were assessed. Certain morphological features of psoriatic epidermis were evident in cytokine-stimulated RHEs, including hypogranulosis and parakeratosis. In addition, RHEs responded to a cytokine mix in a dose-dependent manner by expressing genes and proteins associated with impaired keratinocyte differentiation (keratin 10/K10, loricrin), innate immune responses (S100A7, DEFB4, elafin) and inflammation (IL-1α, IL-6, IL-8, IL-10, IL-12/23p40, IL-36γ, GM-CSF and IFNγ) typical of psoriasis. These disease-relevant changes in morphology, gene transcription and cytokine production were robustly attenuated by pharmacologically blocking TNFα/IL-17A-induced NF-κB activation with IKK-2 inhibitor IV. Conversely, inhibition of IL-22-induced JAK1 signalling with ABT-317 strongly attenuated morphological features of the disease but had no effect on NFκB-dependent cytokine production, suggesting distinct mechanisms of action by the cytokines driving psoriasis. These data support the use of cytokine-induced RHE models for identifying and targeting keratinocyte signalling pathways important for disease progression and may provide translational insights into novel keratinocyte mechanisms for novel psoriasis therapies.
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ABT-317; IKK-2 inhibitor IV; IL-17A; IL-22; TNFα

Mesh:

Substances:

Year:  2022        PMID: 35213752      PMCID: PMC9283227          DOI: 10.1111/exd.14551

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   4.511


  65 in total

1.  Small Molecule and Pooled CRISPR Screens Investigating IL17 Signaling Identify BRD2 as a Novel Contributor to Keratinocyte Inflammatory Responses.

Authors:  Peter F Slivka; Chen-Lin Hsieh; Alex Lipovsky; Steven D Pratt; John Locklear; Marian T Namovic; Heath A McDonald; Joseph Wetter; Rebecca Edelmayer; Min Hu; Erin Murphy; Marc Domanus; Charles Lu; Ryan Duggan; Jacob King; Victoria E Scott; Diana Donnelly-Roberts; Anthony Slavin; Sujatha Gopalakrishnan; Namjin Chung; Eric R Goedken
Journal:  ACS Chem Biol       Date:  2019-04-15       Impact factor: 5.100

2.  RNA interference in keratinocytes and an organotypic model of human epidermis.

Authors:  Cory L Simpson; Shin-ichiro Kojima; Spiro Getsios
Journal:  Methods Mol Biol       Date:  2010

3.  Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model.

Authors:  Shigetoshi Sano; Keith Syson Chan; Steve Carbajal; John Clifford; Mary Peavey; Kaoru Kiguchi; Satoshi Itami; Brian J Nickoloff; John DiGiovanni
Journal:  Nat Med       Date:  2004-12-12       Impact factor: 53.440

4.  Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation.

Authors:  Katia Boniface; Caroline Diveu; Franck Morel; Nathalie Pedretti; Josy Froger; Elisa Ravon; Martine Garcia; Emilie Venereau; Laurence Preisser; Emmanuel Guignouard; Gérard Guillet; Guy Dagregorio; Jérôme Pène; Jean-Pierre Moles; Hans Yssel; Sylvie Chevalier; François-Xavier Bernard; Hugues Gascan; Jean-Claude Lecron
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

5.  IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes.

Authors:  Katia Boniface; François-Xavier Bernard; Martine Garcia; Austin L Gurney; Jean-Claude Lecron; Franck Morel
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

Review 6.  Immunology of psoriasis.

Authors:  Michelle A Lowes; Mayte Suárez-Fariñas; James G Krueger
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

Review 7.  Structure and signalling in the IL-17 receptor family.

Authors:  Sarah L Gaffen
Journal:  Nat Rev Immunol       Date:  2009-07-03       Impact factor: 53.106

8.  Expression of NF-kappaB in epidermis and the relationship between NF-kappaB activation and inhibition of keratinocyte growth.

Authors:  J Takao; T Yudate; A Das; S Shikano; M Bonkobara; K Ariizumi; P D Cruz
Journal:  Br J Dermatol       Date:  2003-04       Impact factor: 9.302

9.  IL-22 increases the innate immunity of tissues.

Authors:  Kerstin Wolk; Stefanie Kunz; Ellen Witte; Markus Friedrich; Khusru Asadullah; Robert Sabat
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

10.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.

Authors:  Claire L Langrish; Yi Chen; Wendy M Blumenschein; Jeanine Mattson; Beth Basham; Jonathan D Sedgwick; Terrill McClanahan; Robert A Kastelein; Daniel J Cua
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.